NCT00054249已完成2 期
A Phase II Study Of Intravenous T900607-Sodium In Subjects With Previously Treated Gastric Carcinoma
University Hospitals Seidman Cancer Center2 个研究点 分布在 1 个国家开始时间: 2002年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.
详细描述
OBJECTIVES:
- Determine the response rate (complete and partial) in patients with previously treated gastric or gastroesophageal junction carcinoma treated with T900607. (Gastric carcinoma closed to accrual as of 02/04.)
- Determine the duration of response and time to disease progression in patients treated with this drug.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the safety profile of this drug in these patients.
OUTLINE: This is an open-label, multicenter study.
Patients receive T900607 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed gastric or gastroesophageal junction carcinoma (gastric carcinoma closed to accrual as of 02/04)
- •Must have received 1 or 2 prior chemotherapy regimens for gastric carcinoma (gastric carcinoma closed to accrual as of 02/04)
- •Bidimensionally measurable disease
- •At least 1 lesion that is at least 10 mm by CT scan
- •No CNS metastases or carcinomatous meningitis
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Karnofsky 70-100%
- •Life expectancy
- •At least 12 weeks
- •Hematopoietic
- •Absolute neutrophil count ≥ 1,500/mm^3*
- •Platelet count ≥ 100,000/mm^3*
- •Hemoglobin ≥ 8.5 g/dL* NOTE: *Independent of growth factor or transfusion support
- •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- •AST and ALT ≤ 3 times ULN
- •INR ≤ 1.5 (unless receiving anticoagulants)
- •Albumin > 2.5 g/dL
- •Creatinine ≤ 2 times ULN
- •Cardiovascular
- •No New York Heart Association class III or IV heart disease
- •LVEF ≥ 50%
- •No acute anginal symptoms
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 3 months after study participation
- •Able to comply with study procedures and follow-up
- •No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- •No severe infection
- •No other concurrent severe medical condition or comorbidity that would preclude study participation
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •More than 7 days since prior growth factors or blood transfusions
- •No concurrent therapeutic biological response modifier therapy
- •No concurrent immunotherapy
- •Chemotherapy
- •See Disease Characteristics
- •No other concurrent cytotoxic chemotherapy
- •Endocrine therapy
- •No concurrent hormonal therapy
- •Radiotherapy
- •No concurrent radiotherapy (including palliative radiotherapy)
- •More than 4 weeks since prior major surgery
- •More than 4 weeks since prior investigational agents
- •No other concurrent investigational anticancer therapy
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
T900607 in Treating Patients With Unresectable Liver CancerLiver CancerNCT00054262University Hospitals Seidman Cancer Center
Unknown
2 期
T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous ChemotherapyLung CancerNCT00022243Tularik
已完成
1 期
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00017017Memorial Sloan Kettering Cancer Center
Unknown
2 期
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck CancerHead and Neck CancerNCT00022217Matrix Pharmaceutical
已完成
2 期
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RTCentral Nervous System Tumor, PediatricNCT00084838Dana-Farber Cancer Institute25